<DOC>
	<DOCNO>NCT00045604</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth tumor cell block enzymes necessary tumor cell growth . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining imatinib mesylate chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine imatinib mesylate irinotecan cisplatin treat patient extensive-stage small cell lung cancer</brief_summary>
	<brief_title>Imatinib Mesylate Chemotherapy Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose imatinib mesylate administer irinotecan cisplatin patient extensive stage small cell lung cancer . - Determine effect imatinib mesylate irinotecan metabolism cytochrome p450 system patient . - Determine response rate , time progression , survival patient treat regimen . OUTLINE : This dose-escalation study imatinib mesylate . Patients receive irinotecan IV 30 minute day 1 , 8 , 15 cisplatin IV 60 minute day 1 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . Patients also receive oral imatinib mesylate twice daily begin day 22 course 1 continue disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos imatinib mesylate maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 18 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm small cell lung cancer Extensive stage disease Measurable evaluable indicator lesion No symptomatic uncontrolled brain leptomeningeal involvement PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic WBC least 4,000/mm3 Platelet count least 160,000/mm3 Hemoglobin least 10 g/dL Hepatic Bilirubin great 1 mg/dL AST great 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 5 time ULN Renal Creatinine le 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No uncontrolled cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month study No active cancer except previously treat carcinoma situ , non melanoma skin cancer , stage I prostate cancer No ongoing active infection No psychiatric illness social situation would preclude study No concurrent uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy except noncancer condition ( e.g. , lowdose methotrexate rheumatoid arthritis ) Endocrine therapy Not specify Radiotherapy At least 2 week since prior radiotherapy major bone marrowcontaining area Surgery Not specify Other No concurrent warfarin therapeutic anticoagulation Lowmolecular weight heparin heparin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>